Related to Lonza to Provide Cell-Line and Process-Development Services for Athera’s mAb

• Genzyme and Isis Report Positive Phase III Data from Familial Hypercholesterolemia Trial
  
• Researchers Uncover Potential Gene Target for Lone Atrial Fibrillation
  
• PolyTherics and Zealand Ink PEGylated Peptide Therapeutics Collaboration
  
• Abbott to Use BG Medicine’s Heart-Failure Biomarker in Point-of-Care Test
  
• Horizon Acquires Human Isogenic Cell Models of DNA Damage Repair from University of Minnesota
  
• Newly Established Firm Aims to Speed Development of Stable Cell Lines and Primary Cells for R&D
  
• SAFC Opens Second High-Potency API Facility in Madison
  
• Recordati Signs Up Esteve as Marketing Partner for Pitavastatin in Spain
  
• Genzyme and Arecor Ally to Advance Protein Therapeutics
  
• SPI-Bio to Supply Aterovax’ sPLA2 Activity Test in Europe for Research Use
  
• BioInvent Cans Contract Manufacturing Activities to Focus on Proprietary Drug Development
  
• ImmunoCellular Therapeutics Taps UPenn to Progress Mid-Stage Glioblastoma Candidate
  
• Plant-Based Protein Production System Developed
  
• AstraZeneca’s Crestor Approved in 19 EU Countries for Preventing Major Cardiovascular Events
  
• SAFC to Invest $6.25M to Fortify Kansas Facility
  
• Critical Biologics to Use Scarab’s Clean Genome E. coli for Production of Phase II Gelsolin Replacement Therapy
  
• CRO Aragen Negotiates Licenses to Cevec’s Human Amniotic Cell Line Expression System
  
• BioTime to Take Over ES Cell International for hESC Lines
  
• Australian Government Commissions DSM to Build Biomanufacturing Facility
  
• DSM Buys Biomanufacturing Technology from Upfront Chromatography